Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?